Latest news with #VMS
&w=3840&q=100)
Business Standard
5 hours ago
- Business
- Business Standard
Procter & Gamble Health rallies 10%, hits 4-year high on strong Q1 results
Procter & Gamble Health share price today Shares of Procter & Gamble Health hit a four-year high at ₹6,475, as they rallied 10 per cent on the BSE in Friday's intra-day trade in an otherwise weak market after the company reported strong earnings for the quarter ended June 2025 (Q1FY26). The stock price of the pharmaceutical company was quoting at its lowest level since April 2021. It had hit a record high of ₹7,499.95 on February 11, 2021. At 02:34 PM; Procter & Gamble Health was trading 7 per cent higher at ₹6,312.10, as compared to 0.40 per cent decline in the BSE Sensex. Q1 results - Procter & Gamble Health Procter & Gamble Health delivered a strong performance with sales of ₹333 crore, up 20 per cent against a year ago, owing to broad-based growth in domestic and exports business. Profit after tax (PAT) stood at ₹66 crore, against ₹17 crore a year ago, due to strong sales growth and one-time impact of impairment in the base period. Commenting on the performance, Milind Thatte, Managing Director, P&G Health India, said, "We are pleased with the continued momentum and strong start to the Financial Year 2025-26. These results are a reflection of our commitment towards addressing the evolving needs of our consumers and healthcare professionals, via superior brand building and go to market initiatives while improving supply chain capabilities'. The company's strategy, centered on a focused portfolio of quality, trusted, and highly recommended brands where performance drives brand choice; superiority (across product, package, brand communication, retail execution and value), constructive disruption and an agile accountable organization, is delivering balanced and sustainable growth results, Milind Thatte said. Opportunities, outlook The healthcare sector in India has undergone a significant transformation, fueled by substantial investments in infrastructural development. Since 2016, the Indian healthcare industry has witnessed a consistent growth trajectory. The consumer healthcare sector shows promising prospects for the future. The company is well-positioned to sustain and strengthen its position in the market. About Procter & Gamble Health Procter & Gamble Health Limited is one of India's largest vitamins, minerals, and supplements (VMS) companies manufacturing and marketing VMS products for a healthy lifestyle and improved quality of life, including Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion. P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Ambi Pur, Ariel, Gillette, Head & Shoulders, Olay, Oral-B, Pampers, Pantene, Tide, Vicks, and Whisper. P&G operates in approximately 70 countries worldwide.
New Straits Times
6 hours ago
- Automotive
- New Straits Times
Plus traffic diversion between Bukit Gambir-Tangkak elevated interchange from Aug 5-Dec 30
KUALA LUMPUR: Plus Malaysia Bhd (Plus) will activate traffic diversion on the route between the Bukit Gambir-Tangkak Elevated Interchange at Km166.79 to Km168.26, in both directions, of the North-South Expressway from Aug 5 to Dec 30. It said the diversion would be activated in stages to enable bridge construction work carried out across the highway by Public Works Department (PWD) contractors. "Highway users are recommended to plan their journey during this period. "They are also advised to obey all traffic signage and instructions issued by Plus staff along the affected area," it said in a statement today. The latest traffic information can be obtained via the Plus application, the PUTRI Virtual Assistant, the X-@plustrafik application and the Variable Message Sign (VMS) displays at selected locations or contact PLUSLine at 1800-88-0000 for emergency assistance. — BERNAMA
Business Times
a day ago
- Business
- Business Times
Family office for Hong Kong's richest builds out hedge fund team
[HONG KONG] A money manager for some of Hong Kong's richest families is building a hedge fund team to allocate money away from private equity after its clients asked for more liquid investments. VMS Group, which has about US$4 billion in assets under management, hired equities veteran Raymond Jook as managing director in April. The team added Kyle Wong and Carmen Tang to form a three-person group that will invest in public markets and build hedge fund strategies over time, managing partner Elton Cheung said. The hires are part of a strategic pivot for the multi-family office that's also making a foray into crypto. The firm has largely focused on private equity and other longer-duration strategies since it was founded two decades ago. The investment firm is affiliated with the billionaire Cheng dynasty that controls New World Development, according to sources familiar with the matter, who asked not to be identified discussing private information. 'Most people identify us as a private equity and primary market specialist,' Cheung said. 'But we have been hearing from clients moaning about the lack of liquidity, so we want to add on new strategies which are much more liquid, like monthly redemption,' he said. VMS declined to comment on a relationship with the Cheng family, saying it does not disclose the identity of its investors. The team plans to build a track record in equities before potentially launching a new equity long/short hedge fund for external investors around year-end, with an initial fund-raising target of more than US$100 million, Cheung said. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up Ultimately, VMS's ambition is to build a platform with multiple strategies such as macro, credit, event-driven and quant, Cheung said. Family offices are trimming private equity after years of increases, while boosting allocations to hedge funds to navigate macroeconomic uncertainty, according to a UBS Group report. Another investment firm, Andon Hong Kong, is opening an office in New York to deepen its push into hedge funds, Bloomberg previously reported. Jook joined from BOCHK Asset Management, where he was head of equities. Before that, he was managing director and chief investment officer at Avant Capital Management (HK), overseeing investment strategies and operations. He also held roles at UBS earlier in his career. Wong was director of financial markets at Kaplan, an education company, for more than a decade, according to his LinkedIn profile. Tang worked for Goldman Sachs earlier in her career. The family office helps manage money for several of the city's billionaire families and runs funds that invest in various sectors, including Internet technology and pharmaceuticals. In 2023, it teamed up with a former executive from Chinese artificial-intelligence (AI) company SenseTime Group to look for early-stage investments in AI. BLOOMBERG
Business Wire
4 days ago
- Business
- Business Wire
Lyten Secures More than $200 Million in Investment to Support its Ongoing Acquisition Strategy
SAN JOSE, Calif. & LUXEMBOURG--(BUSINESS WIRE)--Lyten, the supermaterial applications company and global leader in lithium-sulfur batteries, announced today it has secured more than $200 million in additional equity investment. This brings total investment to date in Lyten to more than $625 million. The additional investment is provided primarily from current investors. Lyten intends to accelerate its acquisition strategy and expansion plans in both the US and Europe with the additional capital. Additionally, Lyten announced today it has acquired the rights to Northvolt's energy storage products, Voltpack Mobile Systems (VMS), Voltrack, and future BESS products currently in development. This is Lyten's third Northvolt-related acquisition since November 2024. The VMS product is already in its third generation, with commercial installations throughout Europe. The core members of Northvolt's energy storage engineering team will be joining Lyten in Stockholm, Sweden, and VMS and future BESS products will be manufactured in Gdansk, Poland. Lyten previously announced the acquisition of two Northvolt assets. In November 2024, Lyten announced the acquisition of Northvolt's Cuberg battery manufacturing facility in California and earlier in July announced its plans to acquire Northvolt Dwa, Europe's largest Battery Energy Storage System (BESS) manufacturing facility, located in Gdansk, Poland. 'We are thrilled by the investment community's response to our expansion strategy,' stated Dan Cook, Lyten CEO and Co-Founder. 'Lyten is seeing immediate demand for its battery products in support of energy independence and national security initiatives in the US and Europe. Drones, defense, datacenters and BESS are all markets seeking battery solutions independent of Chinese supply chains. This capital is focused on rapid, capital-efficient expansion of manufacturing and onboarding world-leading talent in both the US and European markets.' Zia Huque, Lyten investor and General Partner at Prime Movers Lab, added, 'We continue to be impressed by Lyten's ability to grow through acquisitions. This is a testament to both Lyten's technology and its leadership team's experience in private equity, which is unique in the battery industry. The ability to efficiently scale manufacturing capacity is critical for Lyten right now to meet the rapidly growing demand for its products." Lyten intends to immediately restart BESS manufacturing in Gdansk, Poland, upon the close of the previously announced acquisition of Northvolt Dwa and targets product deliveries in the fourth quarter of 2025. Deliveries will initially target existing European customers and then quickly expand to a wide range of global markets, including AI datacenter, industrial, commercial, and grid applications. David Ku, Lyten Investor and former Microsoft Corporate Vice President of AI and CTO of the Artificial Intelligence + Research division, stated, "Success in AI is determined by the ability to deliver abundant, reliable power. Battery energy storage is a critical piece of AI data center infrastructure. Lyten's lithium-sulfur batteries are uniquely positioned to deliver the performance and supply chain independence necessary to meet AI's insatiable need for batteries." Lyten and Northvolt intend to close the transaction of the Northvolt Dwa facility in Poland and Northvolt System's BESS product portfolio in Sweden in the third quarter of 2025. About Lyten Lyten, founded in 2015, is a supermaterial applications company that has received more than $625 million in equity investment and secured LOIs for $650M in financing from the Export Import Bank of the US. Lyten has built a proprietary materials platform, called Lyten 3D Graphene, that it uses to build better performing, lower cost, and decarbonizing products, including its next generation lithium-sulfur battery. Lyten corporate headquarters is in San Jose, CA and European headquarters is in Luxembourg. The company lists more than 540 patents granted or pending and is currently manufacturing in San Jose, CA. In November 2024, Lyten announced the acquisition of Northvolt's battery manufacturing plant in San Leandro, California to scale production to meet the demand for American made batteries. In 2024, Lyten announced its integration into Chrysler's Halcyon Concept electric vehicle, plans to integrate lithium-sulfur into AEVEX Aerospace's unmanned aerial vehicles, and the selection of Lyten Lithium-Sulfur for demonstration on-orbit aboard the International Space Station (ISS), scheduled for launch later in 2025. Lyten was named Fast Company's #8 Most Innovative Energy Company, named to Silicon Valley Defense Journal's Top 100 National Security Companies from 2023 – 2025, and named one of America's Top Green Technology Companies by Time in 2024 and 2025.
West Australian
6 days ago
- Health
- West Australian
Women's symptoms 'overlooked' in menopausal stages
Women going through perimenopause are experiencing debilitating hot flushes and night sweats that are often untreated, as a study reveals the prevalence of symptoms during hormonal transitions. Perimenopause is a transitional period before menopause, where levels of oestrogen begin to decrease, bringing with it a range of symptoms. A first of its kind study of more than 5500 women by Monash University published in The Lancet Diabetes and Endocrinology examined the similarities and differences in symptoms across the stages of menopause. Almost 40 per cent of perimenopausal women in the study experienced debilitating vasomotor symptoms (VMS) such as hot flushes and night sweats. While it was already known that VMS symptoms were typical in menopause, the study showed a new onset was highly specific to perimenopause, senior author Susan Davis said. Other symptoms such as poor memory and low mood were found at various stages, but vaginal dryness was the most distinctive symptom from pre-menopause to perimenopause, she said. Other symptoms such as poor memory and low mood were found at various stages, but vaginal dryness was the most distinctive symptom from pre-menopause to perimenopause, she said. "While other symptoms might emerge in the perimenopausal stage, they lack specificity to that stage as these other symptoms are also common in pre-menopausal women." A major finding in the study was that women with regular cycles but changed menstrual flow and VMS who are classified as pre-menopausal have a similar severity of symptoms as perimenopausal women. "This finding supports the likelihood of perimenopause commencing before menstrual cycles vary by at least a week, and that women whose periods have become much heavier or much lighter and who also have VMS should be considered as having entered their perimenopause," Professor Davis said. The research was expected to transform women's health treatment, particularly in menopause, which had been overlooked for too long, Monash Women's Health Alliance chair Jill Hennessy said. "Too many go untreated for debilitating symptoms like hot flushes and night sweats," she said. "By defining the symptoms that truly mark this transition, this study empowers women and clinicians alike with better knowledge and tools to improve women's health and wellbeing." The study authors hoped the findings would improve how medical professionals identified and managed transitions in menopause. Many women were overlooked in being classified within a menopausal stage if they had regular cycles or no longer menstruated due to a hysterectomy, first author Rakib Islam said. "Our findings support a more symptom-based approach, enabling earlier recognition of perimenopause and more timely care," he said.
